bio chat
to the poorest countries
in the world – A great
illustration is Serum
Institute’s Meningococcal
A vaccine which now
covers 100 percent of
GAVI supply of 70 million
doses for 15 countries.
Prior to Serum the
vaccine was supplied
only by multinationals
producing in high cost
countries and was not
affordable to majority of
the underdeveloped and
developing world where
it was needed most.
India accounted for more
32
BioVoiceNews | April 2017
than 60 percent of the
vaccines supplied to GAVI
in 2014 and supplies
more than 80 percent of
GAVI procurement for 4
vaccines.
How has been the
growth of the sector so
far and the prediction
for next few years?
Our analysis indicates
that the industry grew to
approximately $1 billion
in 2015 with a robust
CAGR of 25 percent
between 2011 and 2015.
Exports are the dominant
revenue source for Indian
vaccine industry today,
accounting for a dominant
69 percent share in value.
We expect this robust
growth to be sustained
with support from
increasing public
awareness and high
government focus on
enhancing vaccination
coverage. Private market
for discretionary vaccines
has also been rapidly
growing and we expect
the trend to continue